Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Research & Development (2016 - 2025)

Corcept Therapeutics' Research & Development history spans 10 years, with the latest figure at $64.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 7.74% year-over-year to $64.9 million; the TTM value through Dec 2025 reached $254.9 million, up 3.25%, while the annual FY2025 figure was $254.9 million, 3.25% up from the prior year.
  • Research & Development for Q4 2025 was $64.9 million at Corcept Therapeutics, down from $68.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $70.3 million in Q4 2024 and bottomed at $28.1 million in Q3 2021.
  • The 5-year median for Research & Development is $44.4 million (2023), against an average of $46.6 million.
  • The largest annual shift saw Research & Development dropped 17.06% in 2021 before it surged 48.85% in 2023.
  • A 5-year view of Research & Development shows it stood at $28.5 million in 2021, then grew by 28.88% to $36.8 million in 2022, then soared by 48.85% to $54.7 million in 2023, then rose by 28.5% to $70.3 million in 2024, then decreased by 7.74% to $64.9 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Research & Development are $64.9 million (Q4 2025), $68.8 million (Q3 2025), and $60.5 million (Q2 2025).